22 September 2021
Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that it is now a member and will hold a Board position on the Council on Radionuclides and Radiopharmaceuticals, Inc (CORAR), a trade association and leading voice of the radionuclide and radiopharmaceutical industry in North America.
CORAR is an association comprised of companies that manufacture and distribute radiopharmaceuticals, radionuclides, and sealed sources primarily used in medicine and life science research in the U.S. CORAR monitors and advocates for regulations and legislation at the U.S. Federal, State, and Local government levels. Specifically, CORAR focuses its advocacy efforts on manufacturing, transportation, safety, security, and government reimbursement that impact the radiopharmaceutical, radionuclide, and sealed source industries. CORAR pursues a proactive agenda which includes education of the U.S. Congress and regulatory bodies on the benefits of radiopharmaceuticals, radionuclides, and sealed sources to the medical and life science fields.
Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very pleased to be a member company of CORAR and are looking forward to working together with its other members on shaping and improving the regulatory agenda around the use of radiopharmaceuticals, from the manufacturing stage through to the way we treat patients in the clinic. We believe that Targeted Copper Theranostics (TCT) hold great promise in the field of radiopharmaceuticals, including manufacturing, logistical and clinical benefits and are excited to continue working with the industry to advocate for the broader use of TCT, build infrastructure to support their growth and inform the market of the advantages associated with copper-based radiopharmaceuticals in pursuit of our ultimate goal of improving treatment outcomes for children and adults with cancer.”
CORAR currently consists of 16 member companies, including Advanced Accelerator Applications, Cardinal Health Nuclear & Precision Healthcare Solutions, Curium, Lantheus Holdings, Inc., Jubilant Radiopharma, NorthStar Medical Technologies, LLC, SHINE Medical Technologies, and other organisations prominent in the field of radiopharmaceuticals.
CORAR Executive Director, Michael J. Guastella, commented, “We are pleased to welcome Clarity as a new member of CORAR with representation on our Board of Directors. Clarity’s TCT platform of products will help pave the way for the broader use of theranostic pairings to enhance patient access to innovative radiopharmaceuticals and state-of-the art care.”
This announcement has been authorised for release by the Board.
About CORAR
The Council on Radionuclides and Radiopharmaceuticals, Inc. is a Washington, DC based trade association that is a leading voice of the radionuclide, radiopharmaceutical, and industrial radioisotope industries in North America. CORAR represents the major manufacturers and distributors of radiopharmaceuticals, radioactive sources and medical isotopes primarily used in the United States for therapeutic and diagnostic nuclear medical applications (referred to as nuclear medicine) and, in some cases, for industrial, environmental, and biomedical research and quality control.
www.corar.org
About Clarity
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com
Simon Hinsley
Investor/Media Relations
+61 401 809 653
simon@nwrcommunications.com.au
